TNFRSF10B and melanoma: Importantly, competition experiments with a commercial antibody directed to TRAIL-R2 significantly inhibited the scDb-dependent up-regulation of CD25, CD137, and CD69 in T lymphocytes co-cultured with melanoma target cells (Figure 4D), indicating that T-cell activation requires the scDb to bind to both specificities.